Rhumbline Advisers Acquires 15,792 Shares of Edwards Lifesciences Corporation $EW

Rhumbline Advisers lifted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 1.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 1,111,787 shares of the medical research company’s stock after buying an additional 15,792 shares during the period. Rhumbline Advisers’ holdings in Edwards Lifesciences were worth $86,464,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Krilogy Financial LLC bought a new stake in Edwards Lifesciences during the third quarter worth about $427,000. Advisors Asset Management Inc. grew its stake in Edwards Lifesciences by 10.7% in the third quarter. Advisors Asset Management Inc. now owns 17,883 shares of the medical research company’s stock valued at $1,391,000 after purchasing an additional 1,727 shares in the last quarter. Stratos Wealth Partners LTD. increased its position in shares of Edwards Lifesciences by 39.4% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 14,659 shares of the medical research company’s stock worth $1,140,000 after purchasing an additional 4,142 shares during the last quarter. MQS Management LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter worth approximately $307,000. Finally, Wealthfront Advisers LLC raised its stake in shares of Edwards Lifesciences by 7.6% during the 3rd quarter. Wealthfront Advisers LLC now owns 29,662 shares of the medical research company’s stock worth $2,307,000 after purchasing an additional 2,083 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $76.39 on Friday. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89. The company has a market capitalization of $44.33 billion, a price-to-earnings ratio of 41.74, a PEG ratio of 3.03 and a beta of 0.94. The company has a 50-day simple moving average of $83.55 and a 200 day simple moving average of $81.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. During the same period in the prior year, the company earned $0.59 earnings per share. The firm’s revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

EW has been the topic of a number of recent analyst reports. Truist Financial set a $89.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Wednesday. National Bank Financial set a $92.00 price objective on shares of Edwards Lifesciences in a research report on Friday, October 31st. Mizuho upped their target price on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, October 31st. The Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday. Finally, Evercore reissued an “outperform” rating and set a $94.00 price target on shares of Edwards Lifesciences in a research report on Monday, January 5th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $96.14.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,340 shares of the stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total transaction of $971,384.40. Following the transaction, the vice president owned 31,870 shares in the company, valued at $2,729,984.20. This trade represents a 26.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of the business’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at approximately $3,370,184.06. The trade was a 16.18% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 43,804 shares of company stock valued at $3,699,082. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences News Summary

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Analyst upgrades and reiterated buys lift longer‑term outlook — Wells Fargo raised its price target to $100 and moved to “overweight,” while BTIG and several other firms reiterated Buy ratings with ~$103 targets, supporting upside expectations. Article Title
• Positive Sentiment: Strong revenue growth and TAVR momentum highlighted on the earnings call — Management emphasized sustained Transcatheter Aortic Valve Replacement (TAVR) and other structural‑heart growth drivers; the company is leaning into growth after the quarter. Article Title
• Positive Sentiment: Options/contrarian take: some traders see the post‑earnings weakness as a buying opportunity — commentary suggests cleared uncertainty after results could support a tactical bullish trade. Article Title
• Neutral Sentiment: Mixed earnings print — Q4 revenue topped expectations and grew year‑over‑year, but EPS missed estimates. Revenue strength supports the growth narrative, while the EPS shortfall creates near‑term uncertainty. Article Title
• Neutral Sentiment: Sector context — Comparative coverage of healthcare earnings (AstraZeneca vs. Edwards vs. Zimmer Biomet) highlights macro/peer performance but is not specific to EW’s fundamentals. Article Title
• Negative Sentiment: Shareholder‑rights notice from Halper Sadeh LLC adds legal/uncertainty risk — a public call encouraging shareholders to contact the firm can prompt selling or increase perceived governance risk. Article Title

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.